J J Ifthikharuddin

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab
    J J Ifthikharuddin
    Department of Hematology Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA
    Am J Hematol 65:171-3. 2000
  2. ncbi request reprint Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002
  3. ncbi request reprint Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation
    S Q Fu
    Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P Wilmot Cancer Center, University of Rochester, New York 14642, USA
    Blood Cells Mol Dis 28:315-21. 2002
  4. ncbi request reprint Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report
    G L Phillips
    The James P Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
    Semin Oncol 31:59-61. 2004

Collaborators

Detail Information

Publications4

  1. ncbi request reprint CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab
    J J Ifthikharuddin
    Department of Hematology Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA
    Am J Hematol 65:171-3. 2000
    ..We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment...
  2. ncbi request reprint Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients
    Jane L Liesveld
    Blood and Marrow Transplant Program, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Biol Blood Marrow Transplant 8:662-5. 2002
    ..This study demonstrates the feasibility and significant cost savings of using oral VAL for HSV prophylaxis...
  3. ncbi request reprint Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation
    S Q Fu
    Blood and Marrow Stem Cell Transplant Program, Department of Internal Medicine and The James P Wilmot Cancer Center, University of Rochester, New York 14642, USA
    Blood Cells Mol Dis 28:315-21. 2002
    ..The CFU-GM/CD34+ ratio is an apparent predictor of earlier platelet engraftment, suggesting that the ratio reflects the engraftment potential of mobilized donor progenitor cells...
  4. ncbi request reprint Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report
    G L Phillips
    The James P Wilmot Cancer Center, BMT Program, Rochester, NY 14642, USA
    Semin Oncol 31:59-61. 2004
    ..Patient entry at the starting dose (ie, HD-MEL 140 mg/m2) has been completed without the development of severe regimen-related toxicities. This trial is ongoing...